Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges
Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.
How this was made
The 30-second read
Why it matters
The article aggregates fresh earnings beats and misses, providing traders with immediate catalysts for short‑term positioning across several sectors.
Market read
High relevance for traders focused on earnings-driven moves; mixed impact across sectors.
What to watch
CrowdStrike's CTO departure could signal strategic shifts in AI security that are not yet priced in.
Background
Premarket movers roundup covering multiple earnings releases and corporate events ahead of the trading day.
Ticker impact
Deere shares jumped 5.1% after reporting fiscal Q3 earnings of $5.10 EPS and $11B sales, beating estimates.
Potential further premarket rally; watch for follow‑on buying.
Beat on both EPS and revenue, sizable move, and guidance implied.
Wolfspeed fell 10.5% as it posted a Q4 loss of $2.26 per share versus $0.52 expected and revenue $149.6M versus $223.5M consensus.
Further downside expected in intraday trading.
Large miss on both earnings and revenue, reinforced by analyst hold rating.
CrowdStrike shares fell 2.8% after its CTO announced departure to start an AI‑focused cybersecurity fund.
Modest further decline possible.
CTO exit may affect product roadmap perception.
Advance Auto Parts stock plunged 15.9% after Q2 results showed adjusted EPS of $1.03, boosted by $0.31 tariff refunds, implying core earnings of $0.72.
Potential continued sell‑off.
One‑time items masked underlying weakness.
Etsy rose 3.9% after BofA upgraded it to Buy and raised the price target to $105, citing strong mobile sales and growth pillars.
Likely modest upside in the near term.
Analyst endorsement supports momentum.
Ultragenyx surged 11.1% after FDA granted accelerated approval to its gene therapy DTX401 for glycogen storage disease type Ia.
Further upside expected as market prices in the approval.
First gene‑therapy approval and priority review voucher add material value.
Moderna fell 13% in pre‑market trading after a sharp rally the prior day, following its Phase 3 cancer‑vaccine trial results with Merck.
Potential continued pull‑back.
No fresh catalyst, just reversal of earlier gains.
Market effects
Positive earnings for Deere may lift industrial equipment sector; Wolfspeed miss could pressure semiconductor stocks.
U.S. pre‑market activity reflects broader market sentiment ahead of earnings season.
Limited; primarily U.S. equity market focus.
Counterpoint
Wolfspeed's deep loss may be a buying opportunity if the market overreacts.
Key entities
- CompanyDeere
Agricultural and construction equipment maker.
- CompanyWolfspeed
Semiconductor manufacturer.
